Actinium Pharmaceuticals has unveiled ATNM-400, a pioneering radiotherapy designed to treat advanced prostate cancer by utilizing Actinium-225. Unlike traditional therapies that focus on prostate-specific membrane antigen (PSMA), ATNM-400 employs a novel, non-PSMA targeting approach, potentially offering treatment options for patients who do not respond to existing PSMA-based therapies.​

Actinium-225 is a potent alpha-emitting radioisotope known for delivering high-energy radiation over short distances, effectively damaging cancer cells while minimizing harm to surrounding healthy tissue. This characteristic makes it particularly suitable for targeting tumors with precision.​

The development of ATNM-400 represents a significant advancement in prostate cancer treatment, especially for cases that are resistant to conventional therapies. By introducing a non-PSMA targeting mechanism, this therapy could address a critical unmet need in oncology.​

The company plans to conduct further research and clinical trials to evaluate the safety and efficacy of ATNM-400. The company remains committed to advancing cancer treatment through innovative radiotherapeutic solutions.

Source.